Biopharma M&A’s Busy Pace Expected To Continue During 2023’s Second Half

 
• By Joseph Haas

Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at $1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.

M&A
Current trends suggest smaller bolt-on deals remain the order of the day • Source: Shutterstock

More from Deals

More from Business